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Round table discussion
A sexual health prevention priority
Stephen Peckham a & Alison Hann b
Wittet and Tsu are right to point to the link between cervical 
cancer deaths and achieving the MDGs and the inequity in 
the burden of cervical cancer between developed and devel-
oping countries. Any programme that reduces cervical cancer 
incidence and mortality rates in low-income and lower 
middle-income countries is clearly to be welcomed. Ad-
dressing women’s welfare, family education and thus poverty 
through screening, treatment and prevention will play an 
important role in tackling inequalities, although access to 
screening and vaccination is likely to be inequitable if pro-
grammes are not provided in a systematic and comprehensive 
way. We would argue, though, that cervical cancer screening 
and HPV vaccination should be seen as integral parts of, 
rather than separate from or instead of, a wider sexual health 
promotion programme.
Cervical cancer prevention can be viewed in a similar way 
to any other sexually transmitted infection. Screening women 
for cervical cancer is clearly important but a comprehensive and 
universal screening programme requires substantial resources 
and infrastructure and so the opportunity costs of such a 
programme need to be carefully considered. All cancer screen-
ing programmes result in unnecessary intervention or lack of 
intervention due to the sensitivity and specificity of tests that 
can be costly in terms of public spending but also in personal 
anxiety and distress.1–3 As Wittet and Tsu report, however, 
new “see and treat” programmes will make an important con-
tribution to cervical cancer treatment.
The recently developed HPV vaccine offers some hope 
in reducing the levels of cervical cancer but concerns have 
been expressed about its efficacy and the usefulness of vac-
cination programmes – particularly with regard to long-term 
effects and that it only protects against 4 out of the 200 HPV 
viruses. Key questions need to be asked about how vaccina-
tion is offered and to whom. It is only effective in women if 
given before commencing (heterosexual) sexual activity and 
herd immunity will only be achieved if both young men and 
women are vaccinated. Vaccination programme effectiveness 
would also need to be based on known rates of HPV infec-
tion as cervical cancer can also be caused by strains other 
than those for which the vaccine provides protection. Studies 
in the United States of America suggest that the incidence 
for types 16 and 18 is significantly lower than previously 
thought, that infection rates vary by age and most HPV 
infections are asymptomatic.4–7
This is an important point when considering the pri-
mary prevention of cervical cancer and HPV infection. 
Cervical cancer is usually a sexually transmitted disease, yet as 
many as two-thirds of women who are infected with the HPV 
virus will not develop cervical cancer. Primary prevention strat-
egies providing factual information regarding transmission of 
sexually transmitted infection (STI) and the teaching of safer sex 
negotiation skills are potentially highly effective at a relatively low 
cost.8 Condom use has been shown to help prevent the transmis-
sion of the HPV virus as well as other STIs. However, in many 
circumstances it is not always possible for women to negotiate 
the use of the condom, especially within marriage. Of particu-
lar interest, therefore, are current studies being undertaken in 
Nairobi and Zimbabwe to examine the use of the diaphragm as a 
tool to prevent the transmission of not only HPV, but also HIV 
and other STIs.9,10 The advantage of the diaphragm for women 
is that her partner is not necessarily aware that she is using the 
device, which can be cleaned and reused.
While of obvious benefit and importance, cervical can-
cer screening programmes and HPV vaccination are not in 
themselves totally effective strategies. Screening may detect 
early (or more advanced) lesions but this is not without 
problems. Likewise, a population vaccination programme 
for HPV also raises questions that have, so far, not been 
answered satisfactorily. Primary prevention through educa-
tion and promotion of safe sexual practices must, therefore, 
remain a key plank of any programme aimed at reducing 
cervical cancer deaths in the long term and substantially con-
tributing to the MDGs.  ■
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Cervical cancer prevention and the 
Millennium Development Goals
Jacques Milliez a
Cervical cancer, a complication of HPV infection, is the sec-
ond most common cancer in women, with 500 000 new cases 
each year worldwide, 80% of which occur in low-resource 
countries in Africa, Latin America and south-east Asia. More 
than half of women with cervical cancer will die, with deaths 
projected to rise by almost 25% over the next 10 years accord-
ing to WHO.1 In Europe and the United States of America, a 
woman has a 70% chance of surviving cervical cancer whereas 
the chance of survival is only 58% in Thailand, 42% in India, 
and 21% in sub-Saharan Africa.1  In low-resource countries, 
only 41% of women with cervical cancer have access to ap-
propriate treatment.1 Now that immunization against HPV 
is available, will it meet its expectations?
In medically advanced countries, about 30–40% of 
women do not comply with available cervical cancer screen-
ing.2  Whether these women will encourage their teenage 
daughters to have the HPV vaccine is questionable and 
depends strongly on health insurance coverage. In addition, 
immunization against the carcinogenetic HPV strains 16 and 
18 only prevents 70% of cervical cancers.3 Therefore, it does 
not exempt women from further regular cervical screening 
when also considering that the duration and optimal protec-
tion of the initial immunization is unknown and that boys 
are not yet included in the immunization programme.4
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In low-resource countries where cervical cancer screen-
ing programmes and treatments are scarce or absent, HPV 
vaccine raises considerable expectations, but just as many 
objections. HPV subtypes vary between regions in the world 
and the strains targeted by the currently marketed vaccines 
may not prevail in low-resource countries where no extensive 
epidemiologic study of HPV-typing has been conducted. A 
full immunization procedure, three shots over six months, 
is expected to cost US$ 360.1 Such a cost is unaffordable 
for the one billion individuals living on less than US$ 1 
per day, unless the vaccine is distributed by state-subsidized 
programmes. Health authorities in low-resource countries, 
already overwhelmed with public health demands, will have 
to set priorities when allocating limited resources. The same 
painful choices are now imposed on international agencies 
and private foundations with the advent of the HPV vaccine, 
which puts an additional burden on their available funding. 
Equity requires dividing the means according to the needs, 
provided a hierarchy can be established among those needs. 
Given the HIV epidemic, the devastation caused by malaria 
or tuberculosis, maternal mortality that is responsible for 
twice as many women’s deaths as cervical cancer, and the 
four million infants dying each year of avoidable disease, it 
is likely that the HPV vaccine will be given a low priority. 
Furthermore, considering that famine is endemic in at least 37 
countries, urgent wheat, rice and millet provision competes 
with the supply of vital drugs. The World Trade Organiza-
tion and WHO compete in spreading their endeavours with 
shrinking funds. If the Monterrey consensus  (which was the 
outcome of the United Nations International Conference 
on Financing for Development in 2002)5 pledge that urged 
developed countries to divert 0.7% of gross national product 
to worse-off populations is not fulfilled, it is very likely that 
the 2015 MDGs will trail away, regrettably cervical cancer 
prevention above all.  ■
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